Larché M - Search Results

1

Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.

Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, Buhot C, Verhoef A, Maillère B, Kay AB, Larché M. Worm M, et al. Among authors: larche m. J Allergy Clin Immunol. 2011 Jan;127(1):89-97, 97.e1-14. doi: 10.1016/j.jaci.2010.11.029. J Allergy Clin Immunol. 2011. PMID: 21211644 Clinical Trial.

2

The potential of peptide immunotherapy in allergy and asthma.

Ali FR, Kay AB, Larché M. Ali FR, et al. Among authors: larche m. Curr Allergy Asthma Rep. 2002 Mar;2(2):151-8. doi: 10.1007/s11882-002-0010-5. Curr Allergy Asthma Rep. 2002. PMID: 11892095 Review.

3

Peptide-based vaccines in the treatment of specific allergy.

Alexander C, Kay AB, Larché M. Alexander C, et al. Among authors: larche m. Curr Drug Targets Inflamm Allergy. 2002 Dec;1(4):353-61. doi: 10.2174/1568010023344562. Curr Drug Targets Inflamm Allergy. 2002. PMID: 14561182 Review.

4

Allergen immunotherapy with cat allergen peptides.

Kay AB, Larché M. Kay AB, et al. Among authors: larche m. Springer Semin Immunopathol. 2004 Feb;25(3-4):391-9. doi: 10.1007/s00281-003-0146-y. Epub 2003 Sep 30. Springer Semin Immunopathol. 2004. PMID: 15007637 Review.

5

T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity.

Verhoef A, Alexander C, Kay AB, Larché M. Verhoef A, et al. Among authors: larche m. PLoS Med. 2005 Mar;2(3):e78. doi: 10.1371/journal.pmed.0020078. Epub 2005 Mar 29. PLoS Med. 2005. PMID: 15783262 Free PMC article. Clinical Trial.

6

Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M, Hafner RP. Patel D, et al. Among authors: larche m. J Allergy Clin Immunol. 2013 Jan;131(1):103-9.e1-7. doi: 10.1016/j.jaci.2012.07.028. Epub 2012 Sep 13. J Allergy Clin Immunol. 2013. PMID: 22981787 Free article. Clinical Trial.

7

One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence.

Pfaar O, Bousquet J, Durham SR, Kleine-Tebbe J, Larché M, Roberts G, Shamji MH, Gerth van Wijk R. Pfaar O, et al. Among authors: larche m. Allergy. 2022 Feb;77(2):454-468. doi: 10.1111/all.15023. Epub 2021 Sep 27. Allergy. 2022. PMID: 34315190 Review.

8

Peptide-mediated immune responses in specific immunotherapy.

Haselden BM, Kay AB, Larché M. Haselden BM, et al. Among authors: larche m. Int Arch Allergy Immunol. 2000 Aug;122(4):229-37. doi: 10.1159/000024403. Int Arch Allergy Immunol. 2000. PMID: 10971112 Review.

9

Cat allergen peptide immunotherapy reduces CD4(+) T cell responses to cat allergen but does not alter suppression by CD4(+) CD25(+) T cells: a double-blind placebo-controlled study.

Smith TR, Alexander C, Kay AB, Larché M, Robinson DS. Smith TR, et al. Among authors: larche m. Allergy. 2004 Oct;59(10):1097-101. doi: 10.1111/j.1398-9995.2004.00601.x. Allergy. 2004. PMID: 15355469 Clinical Trial.

10

The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects.

Alexander C, Tarzi M, Larché M, Kay AB. Alexander C, et al. Among authors: larche m. Allergy. 2005 Oct;60(10):1269-74. doi: 10.1111/j.1398-9995.2005.00885.x. Allergy. 2005. PMID: 16134993 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

285 results

Search Page